Finally, Kehoe et al. published them in Alzheimer's Research and Therapy on November 25, 2016, which reports that ACE-2 activity was reduced in AD and was an essential regulator of the central classical ACE-1 (angiotensin-converting enzyme-1)/Ang II (Angiotensin II)/AT1R (angiotensin II type 1 receptor) axis of the RAS (renin-angiotensin system). Here, ACE is linked to Alzheimer disease.